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Lower level of insulin-like growth factor-binding protein (IGFBP-1) has been observed in insulin resistance, while
higher level of matrix metalloproteinase-8 (MMP-8) has been linked to obesity. The aim here was to study in
overweight and obese women, typically manifesting with insulin resistance, whether IGFBP-1 and MMP-8 are
related to and reflect systemic low-grade inflammation, metabolism and diet. Fasting serum from overweight and
obese pregnant women (n ¼ 100) in early pregnancy were analysed for IGFBP-1, phosphorylated IGFBP-1
(phIGFBP-1) and MMP-8. High-sensitivity CRP and GlycA were used as markers for low grade inflammation.
GlycA and lipids were quantified using NMR. IGFBP-1 associated negatively with GlycA, evidenced by higher
concentrations in the lowest quartile (median 1.53 (IQR 1.45–1.72)) compared to the highest (1.46 (1.39–1.55))
(P ¼ 0.03). Several lipid metabolites, particularly HDL-cholesterol, correlated inversely with phIGFBP-1
(FDR<0.1). Nutritional status and diet contributed to the levels of IGFBP-1, demonstrated as an inverse corre-
lation with maternal weight (Spearman r ¼ -0.205, P ¼ 0.04) and dietary intake of vitamin A (r ¼ -0.253, P ¼
0.014) and a direct correlation with dietary intake of polyunsaturated fatty acids (Spearman r ¼ 0.222, P ¼ 0.03).
MMP-8 correlated inversely with pyridoxine (r ¼ -0.321, P ¼ 0.002) and potassium (r ¼ -0.220, P ¼ 0.033).
Maternal serum IGFBP-1 may contribute to maternal lipid metabolism in overweight and obese women during
early pregnancy. These findings may be of importance in identification of metabolic disturbances preceding the
adverse metabolic outcomes in pregnancy.1. Introduction
Insulin-like growth factor binding protein 1 (IGFBP-1) regulates the
half-life and activity of IGF-I and II, with multiple actions on host
metabolism and cell growth [1]. Although IGFBP-1 produced by the liver
binds only to a small fraction of circulating IGF-1, it is of importance as
it’s hepatic production is suppressed by food intake, and subsequently
increased glucose and insulin concentrations. On the contrary, at a fast-
ing condition, the production of IGFBP-1 is increased [2]. In addition to
systemic effects, both IGF-1 and IGFBP-1 exert profound local roles
during pregnancy due to their involvement in implantation and fetal
growth. Elevated IGFBP-1 concentrations have been detected in pre-
eclampsia, with both decidua and liver likely contributing to its pro-
duction [3]. Elevated concentration of decidual phosphorylated IGFBP-10 June 2020; Accepted 21 Augu
vier Ltd. This is an open access a(phIGFBP-1) has been used as a risk marker for preterm birth [4] and
amniotic fluid non-phosphorylated IGFBP-1 as a marker for fetal mem-
brane rupture [5]. Further markers include amniotic fluid inflammatory
marker matrix metalloproteinase-8 (MMP-8), the higher concentration of
which has been associated with preterm birth [6, 7].
In addition to their crucial roles in pregnancy, elevated serumMMP-8
concentrations have been linked with obesity [8] and with an increased
risk for cardiovascular disesases [9], while a lower level of IGFBP-1 has
been associated with obesity [10] and with an increased risk for distur-
bances in glucose metabolism [11]. The roles of MMP-8 and IGFBP-1 as
metabolic regulators in pregnancy are less well known, but an inverse
association has been observed between serum IGFBP-1 concentrations
and the maternal body weight or BMI [12, 13, 14]; there are also reports
of an inverse correlation between serum levels of IGFBP-1 and insulin orst 2020
rticle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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women.
The role of serum MMP-8 with regard to maternal metabolism still
awaits clarification. Previous studies in pregnant women have focused on
cases of premature birth; elevated levels of MMP-8 were detected in early
or mid-trimester amniotic fluid [17]. It is not clear whether circulating
levels of IGFBP-1 or MMP-8 are involved in and reflect the inflammatory
status of the mother. They may also be linked with maternal glucose and
lipid metabolism and thus function as potential regulators of maternal
health during pregnancy. In addition, the extent to which IGFBP-1 and
MMP-8may bemodified by dietary intake has not been studied, although
a link with human nutritional status, like obesity, has been reported.
The aim of this study was to investigate whether serum IGFBP-1 in its
non-phosphorylated and phosphorylated forms as well as MMP-8 would
associate with serum markers of low-grade inflammation and the meta-
bolic profile in pregnant women at high risk for metabolic disorders, i.e.
in overweight and obese women. A secondary aim was to evaluate the
relationships of IGFBP-1 and MMP-8 with the degree of obesity as well as
the dietary intake of energy yielding nutrients, vitamins and minerals.
2. Patients and methods
2.1. Study settings
This is a sub-study of a larger mother-infant dietary intervention trial
(ClinicalTrials.gov, NCT01922791) being conducted in Southwest
Finland and the recruitment initiated at October 2013. The study popu-
lation consisted of the first 100 overweight pregnant women who pro-
vided serum samples at baseline (the first study visit took place at less
than 18 wks of pregnancy). Leaflets containing information of the study
were distributed in maternal welfare clinics. In addition, media and so-
cial media were used to inform about the study. Women interested in
participating in the study contacted the project coordinator for further
information and to schedule their first study visit, during which their e.g.
weight, BMI and body fat percentage were measured.
The inclusion criteria for the intervention trial were prepregnancy
BMI25, age >18 years, and early pregnancy (max. 18 weeks of gesta-
tion). Gestational diabetes in current pregnancy, multifetal pregnancy,
and the presence of metabolic or inflammatory disease including type 1
and type 2 diabetes, celiac disease and inflammatory bowel disease were
exclusion criteria. In this cross-sectional study, we measured the serum
concentrations of IGFBP-1 (phosphorylated and non-phosphorylatedTable 1. Characteristics of the women and concentrations of serum biochemical var
pregnancy.
Baseline characteristics, n ¼ 100
Age (years)*
Highly educated with college or university degree
prepregnancy BMI (kg/m2)
gestational weeks at sampling*
weight (kg) at sampling
Smoking before pregnancy (%)
Smoking during pregnancy (%)
Metabolic markers
IGFBP-1 (ng/ml)
phIGFBP-1 (ng/ml)
MMP-8 (ng/ml)
hsCRP (mg/l)
GlycA (mmol/l)
Glucose (mmol/l)
Insulin mU/L
HOMA2-IR
* mean (SD), others, % or median (IQR).
2form) and MMP-8, which were then related to already measured
markers of inflammation (high sensitive C-reactive protein, hsCRP and
Glycoprotein acetylation, GlycA), glucose (fasting glucose and insulin,
Homeostatic model assessment, (HOMA2-IR) and lipid metabolism (lipid
metabolic profile in metabolomics). The study was approved by the
Ethics Committee of the Hospital District of Southwest Finland
(permission number 115/180/2012). Written informed consent was
obtained from all subjects.2.2. Blood sampling and analytical methods of biochemical variables
A fasting (at least 10 h) blood sample was drawn from the antecubital
vein of the women on the morning of the study visit (mean 12.8 (SD 2.5)
weeks of gestation). The serum was separated and analyzed for hsCRP,
insulin and glucose, and the rest of the samples were frozen in aliquots at
-80 C until further analyses.2.3. IGFBP-1 and phIGFBP-1
Concentrations of serum IGFBP-1 and phIGFBP-1 were measured by
two immunoenzymometric assays using monoclonal antibodies (Medix
Biochemica, Espoo, Finland). The IGFBP-1 assay employing monoclonal
antibody 6305 detects the non-phosphorylated and the less phosphory-
lated isoforms of IGFBP-1, while the phIGFBP-1 assay employing
monoclonal antibody 6303 recognizes the highly phosphorylated forms
[18]. The detection limit of both assays was 0.3 ng/ml [19]. The data is
expressed as ng/ml.2.4. MMP-8
MMP-8 was quantified with a solid-phase immunoenzymometric
assay (MMP-8 IEMA, Medix Biochemica, Espoo, Finland [6, 7, 20]. This
sandwich assay uses two monoclonal antibodies against human MMP-8.
Microplate wells are coated with one monoclonal antibody against
MMP-8. The other antibody is conjugated to HRP forming the enzyme
conjugate used to detect the presence of MMP-8. Analyses were per-
formed according to the manufacturer's instructions, and the absorbance
of the solutions in the wells was measured at 414 nm using a microplate
reader (Multiskan, Thermo Fisher Scientific, Vantaa, Finland). The
detection limit was 0.04 ng/ml [21]. The data is expressed as ng/ml.iables (IGFBP-1, phIGFBP-1, MMP-8, hsCRP and GlycA concentrations) in early
29 (5)
50%
29.8 (26.9–32.8)
12.8 (2.5)
83.1 (76.2–92.3)
20/92 (21.7%)
4/88 (4.3%)
47.0 (26.3–76.8)
638.5 (384.8–905.8)
19.0 (12.3–29.8)
4.9 (3.0–8.3)
1.5 (1.4–1.6)
4.8 (4.6–5.0)
10.0 (7.3–13.8)
1.3 (0.9–1.7)
Figure 1. Spearman's correlations between the levels of IGFBP-1 and phIGFBP-1 and serum lipidomic variables. ** FDR<0.1.
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Table 2. Association of phIGFBP-1 and insulin with HDL –particles in a linear regression model.
β (95% CI) R2/P1 P-value
Very large HDL concentration (mol/l)
Insulin (mU/L) -9.5  109 (-1.8  108 to -1.4  109) 0.181/<0.001 0.022
phIGFBP-1 (ng/ml) -1.7  1010 (-2.7  1010 to -6.1  1011) 0.002
prepregnancy BMI (kg/m2) -6.8  109 (-1.8  108 to 4.3  109) 0.229
Very large HDL-total lipids (mmol/l)
Insulin (mU/L) -0.010 (-0.018 to -0.001) 0.181/<0.001 0.002
phIGFBP-1 (ng/ml) -1.7  104 (-2.8  104 to -6.2  105) 0.002
prepregnancy BMI (kg/m2) -0.007 (-0.018 to 0.004) 0.225
Very large HDL-phospolipids (mmol/l)
Insulin (mU/L) -0.005 (-0.009 to -0.001) 0.185/<0.001 0.016
phIGFBP-1 (ng/ml) -8.0  10 5 (-1.3  104 to -2.5  105) 0.004
prepregnancy BMI (kg/m2) -0.004 (-0.009 to 0.002) 0.200
Very large HDL- total cholesterol (mmol/l)
Insulin (mU/L) -0.004 (-0.008 to -0.001) 0.181/<0.001 0.026
phIGFBP-1 (ng/ml) -8.5  105 (-1.4  104 to -3.4  105) 0.001
prepregnancy BMI (kg/m2) -0.003 (-0.008 to 0.002) 0.247
Very large HDL- cholesterol esters (mmol/l)
Insulin (mU/L) -0.003 (-0.006 to -4.9  104) 0.183/<0.001 0.022
phIGFBP-1 (ng/ml) -6.1  105 (- 9.8  105 to -2.5  105) 0.001
prepregnancy BMI -0.002 (-0.006 to 0.002) 0.279
Very large HDL- free cholesterol (mmol/l)
Insulin (mU/L) -0.001 (-0.002 to -1.4  105) 0.169/<0.001 0.047
phIGFBP-1 (ng/ml) -2. 3  105 (-3.8  105 to -8.0  106) 0.003
prepregnancy BMI (kg/m2) -0.001 (-0.003 to 0.001) 0.181
Very large HDL- triglycerides (mmol/l)
Insulin (mU/L) -8.7  105 (-4.4  104 to 3.0  104) 0.069/0.075 0.628
phIGFBP-1 (ng/ml) -6.1  106 (-1.1  105 to -1.0  106) 0.011
prepregnancy BMI (kg/m2) -1.2  104 (-0.001 to 3.7  104) 0.638
Large HDL- triglycerides (mmol/l)
Insulin (mU/L) -4.6  104 (-0.001 to 2.3  104) 0.099/0.018 0.186
phIGFBP-1 (ng/ml) -2.2  105 (-2.2  105 to -4.0  106) 0.005
prepregnancy BMI (kg/m2) -2.5  104 (-0.001 to 0.001) 0.600
HDL3-cholesterol
Insulin (mU/L) -0.001 (-0.003 to 0.001) 0.122/0.006 0.250
phIGFBP-1 (ng/ml) -4.6  105 (-6.6  105 to -1.4  105) 0.003
prepregnancy BMI (kg/m2) -0.002 (-0.004 to 0.001) 0.252
Values are natural log-transformed for linear regression analysis ie. the regression coefficient (β) represent the one-unit change in natural log-scaled phIGFBP-1 (ng/ml),
insulin (mU/L) or prepregnancy BMI kg/m2 associated with the change of respective HDL-particle in the natural-log-scale. R2 ¼ R-square, P1 -value ¼ P-value for
adjusted linear regression, 95%CI ¼ 95% confidence interval for β.
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The hsCRP was analysed using an automated colorimetric immuno-
assay on a Dade Behring Dimension RXL autoanalyzer (Siemens
Healthcare, Camberly, Surrey, UK), glucose was assayed by an enzymatic
method utilizing hexokinase (Cobas 8000 automatic c702-analyzer,
Roche Diagnostics GmbH, Mannheim, Germany), and insulin was
determined with an immunoelectrochemiluminometric assay (a modular
E170 automatic analyzer, Roche Diagnostics GMbH, Mannheim, Ger-
many) in an accredited Turku University Hospital Laboratory which has a
quality control system. HOMA2-IR was calculated from fasting plasma
glucose and fasting insulin using a HOMA calculator (http://www.dtu.
ox.ac.uk/) [22]. GlycA and lipids were quantified from serum samples
using a commercial high-throughput proton NMR, metabolomics plat-
form (Nightingale Health Ltd., Helsinki, Finland) as previously described
[23]. GlycA is a composite nuclear magnetic resonance (NMR) biomarker
of systemic inflammation and consists of N-acetyl sugar groups origi-
nating from multiple acute phase circulating glycoproteins: α1-acid
glycoprotein, haptoglobin, α1-antitrypsin, α1-antichymotrypsin and
transferrin.42.6. Body weight, body mass index and body composition
Prepregnancy BMI (kg/m2) was calculated by dividing self-reported
weight in kilograms, obtained from welfare women clinic records, by
height measured with a wall stadiometer to the nearest 0.1 cm at the
study visit. The weight was measured using an electronic scale and body
fat percentage was measured using air displacement plethysmography
(Bod Pod system, COSMED, Inc., Concord, CA, USA), at the study visit.
2.7. Dietary intake
Three day food diaries were recorded in a week before the study
visit. The subjects were advised on how to record their food intake
and the diaries were checked for completeness and accuracy with the
help of a portion picture booklet. Mean daily dietary intake of energy
and nutrients were calculated using computerized software, Aivo diet
2.0.2.3 (Aivo, Turku, Finland), which uses the Food and Nutrient
Database of the National Institute for Health and Welfare (Fineli
2016).
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The normality of the variables was evaluated by performing the
Kolmogorov-Smirnov normality test and by visual inspection of the his-
tograms. Since not all of the variables were normally distributed, non-
parametric analyses were used, except multiple linear regression which
was conducted with natural-logarithmic transformed variables. We used
the lowest (Q1) and highest (Q4) quartiles of IGFBP-1, phIGFBP-1 and
MMP-8 in the evaluation of the association with the markers of glucose
metabolism and inflammation (Mann Whitney u test). In addition,
Spearman correlation analyses were performed for comparing serum
levels of IGFBP-1, phIGFBP-1 and MMP-8 with serummetabolic markers,
inflammation, diet, prepregnancy BMI, weight and body fat percentage.
The Benjamini–Hochberg (BH) method was used to control for the false
discovery rate of multiple comparisons for the lipidmetabolites. The false
discovery rate, FDR<0.1 was considered as a statistically significant
finding. Multiple linear regression analysis with fasting insulin and pre-
pregnancy BMI were conducted for HDL-particles remaining statistically
significant after BH-correction. The results are shown as median (inter-
quartile range, IQR) or as mean (standard deviation, SD) for the para-
metric characteristics of the women. Statistical analyses were performed
with SPSS for Windows, version 23.0 (IBMCorp., Armonk, NY, USA).
3. Results
Characteristics of the women are shown in Table 1. The women were
studied at mean 12.8 (SD 2.5) weeks of gestation, they were overweight
(52%; BMI 25–30 kg/m2) or obese (48%; BMI>30 kg/m2), the body fat
percentage being 44.5% (39.5–48.5%) (median, IQR). Every other
woman was highly educated with a college or university degree and 44%
were primipara.
The values for the biochemical variables are shown in Table 1. The
concentration of IGFBP-1 correlated inversely with maternal weight at
study visit (Spearman r ¼ -0.205, P ¼ 0.04), whereas neither phIGFBP-1Table 3. Differences in markers of glucose metabolism and inflammation among IGF
IGFBP-1, median ng/ml (range) Q1, n ¼ 25
15.0 (2.5–26.3)
Q2,n ¼ 28
37.5 (27.0-47.0)
Q3,n ¼ 22
62.5 (48.0–76
Low grade inflammation
hsCRP mg/L, all 6.1 (3.8–12.7) 4.3 (2.6–6.6) 4.8 (2.8–8.2)
GlycA mmol/L 1.53 (1.45–1.72) 1.43 (1.33–1.58) 1.50 (1.42–1.6
Glucose metabolism
Insulin mU/L 13.0 (8.5–17.0) 10.5 (8.0–12.8) 10.0 (6.8–15.0
Glucose mmol/L 4.8 (4.6–5.0) 4.7 (4.5–5.0) 4.8 (2.8–8.2)
HOMA2IR 1.7 (1.1–2.2) 1.4 (1.1–1.6) 1.2 (0.9–1.9)
phIGFBP-1, median Q1, n ¼ 25 Q2, n ¼ 25 Q3, n ¼ 25
ng/ml (range) 192.0 (57.0–383.0) 522.2 (390.0–636.0) 769.0 (641.0–
Low grade inflammation
hsCRP mg/L 4.9 (3.1–10.0) 4.7 (2.3–9.4) 4.5 (3.1–6.7)
GlycA mmol/L 1.50 (1.40–1.69) 1.45 (1.32–1.62) 1.53 (1.42–1.6
Glucose metabolism
Insulin mU/L 13.0 (7.2–14.5) 9.0 (7.5–12.0) 10.0 (8.5–13.5
Glucose mmol/L 4.8 (4.6–5.0) 4.7 (4.6–4.9) 4.8 (4.6–5.2)
HOMA2IR 1.6 (1.0–1.9) 1.2 (1.0–1.5) 1.3 (1.1–1.7)
MMP-8, median Q1, n ¼ 25 Q2, n ¼ 26 Q3, n ¼ 24
ng/ml (range) 9.1 (5.0–12.0) 16.3 (13.0–19.0) 23.3 (20.0–29
Low grade inflammation
hsCRP mg/L 4.3 (2.7–8.3) 5.4 (2.8–9.3) 4.4 (2.5–6.3)
GlycA mmol/L 1.46 (1.35–1.58) 1.48 (1.42–1.62) 1.45 (1.34–1.5
Glucose metabolism
Insulin mU/L 10.0 (7.5–13.0) 10.0 (8.8–13.3) 8.0 (7.0–14.3)
Glucose mmol/L 4.8 (4.6–5.1) 4.7 (4.6–5.0) 4.8 (4.6–5.0)
HOMA2IR 1.3 (0.9–1.7) 1.3 (1.1–1.7) 1.0 (0.9–1.8)
5nor MMP-8 displayed any association with weight (P> 0.239). However,
no correlations were observed between prepregnancy BMI (P > 0.063,
for all) or body fat percentage (P> 0.085 for all) and IGFBP-1, phIGFBP-1
or MMP-8 levels. In addition, no difference was detected between over-
weight and obese subjects with respect to their levels of IGFBP-1 (50.0
(30.0–85.0) vs 38.0 (21.0–74.8) ng/ml, respectively, P ¼ 0.093),
phIGFBP-1 (660.0 (397.0–964.0) vs 618.0 (308.5–875.3) ng/ml, P ¼
0.254) or MMP-8 (18.0 (12.0–26.0) vs 20.0 (13.0–32.0) ng/ml, P ¼
0.495).
3.1. Association of IGFBP-1 and phIGFBP-1 with markers of lipid
metabolism
Levels of phIGFBP-1 were related to several lipidomics variables,
particularly to HDL-particles (Figure 1a and b, Supplemental Table 1).
Interestingly, the strongest correlationswere observed between phIGFBP-
1 and the lipids in the larger sized particles, such as very large HDL.When
correcting for multiple testing (FDR<0.1), 18 correlations remained sta-
tistically significant, half of these being (9/18) inverse correlations be-
tween phIGFBP-1 and HDL-particles. In contrast, non-phosphorylated
IGFBP-1 correlatedwith very few lipid variables, and thesewere no longer
statistically significant after correction for multiple testing. When inves-
tigating the relationship between phIGFBP-1 and HDL-related particles,
the associations remained statistically significant even after adjusting
with serum insulin and prepregnancy BMI, the correlation being higher
between phIGFBP-1 and several HDL-related particles when compared to
the that of insulin (Table 2). No correlations were found between MMP-8
and any of the lipid variables (data not shown).
3.2. Association of IGFBP-1, phIGFBP-1 and MMP-8 with inflammatory
markers and glucose metabolism
The lower concentration of IGFBP-1 (lowest quartile) was related to a
higher concentration of GlycA, a novel marker of low gradeBP-1, phlGFBP-1 and MMP-8 quartiles.
.0)
Q4,n ¼ 25
101.0 (77.0–147.0)
P
Kruskall-Wallis
P
Mann-Whitney (Q1-Q4 comparison)
4.3 (2.1–6.8) 0.166 0.051
2) 1.46 (1.39–1.55) 0.060 0.030
) 9.0 (7–11.5) 0.066 0.007
4.7 (4.6–5.0) 0.845 0.576
1.2 (0.9–1.5) 0.080 0.009
Q4,n ¼ 25 P P
902.0) 1140.0 (907.0–1860.0) Kruskall-Wallis Mann-Whitney (Q1-Q4 comparison)
5.1 (3.1–8.2) 0.757 0.756
0) 1.45 (1.39–1.50) 0.258 0.091
) 9.0 (6.0–12.5) 0.191 0.044
4.7 (4.6–5.0) 0.565 0.899
1.2 (0.8–1.6) 0.186 0.047
Q4, n ¼ 25 P P
.0) 39.0 (30.0–64.0) Kruskall-Wallis Mann-Whitney (Q1-Q4 comparison)
5.3 (3.6–8.8) 0.604 0.357
2) 1.53 (1.44–1.71) 0.168 0.132
11.0 (8.0–14.5) 0.404 0.284
4.8 (4.6–5.0) 0.990 0.815
1.4 (1.0–1.9) 0.458 0.347
Figure 2. a: Spearman's correlation between concentrations of IGFBP-1 and
insulin; b: Spearman's correlation between concentrations of IGFBP-1 and
HOMA2-IR.
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grade inflammation, hsCRP were observed (Table 3). Furthermore, there
were no differences detected in GlycA or hsCRP in relation to phIGFBP-1
or MMP-8 when comparing the lowest and highest quartiles.
A lower concentration of IGFBP-1 (lowest quartile) was related to
higher levels of both insulin and HOMA2-IR. The same association was
detected for the phosphorylated form of IGFBP-1 (Table 3). Further, a
statistically significant negative correlation was observed between
IGFBP-1 and insulin (Spearman r ¼ -0.270, P ¼ 0.007) (Figure 2a) and
HOMA2-IR (r ¼ -0.260, P ¼ 0.009) (Figure 2b). No differences in the
variables reflecting glucose metabolism were detected between the
highest and lowest quartiles of MMP-8, nor when comparing all the
quartiles of IGFBP, phIGFBP or MMP-8. Further, no correlations were
detected between IGFBP-1 and glucose or between the levels of phIGFBP-
1 or MMP-8 with those of glucose, insulin or HOMA2-IR (data not
shown).
3.3. Association of dietary intakes of nutrients with IGFBP-1, phIGFBP-1
and MMP-8
A weak, but nonetheless statistically significant positive correlation
was observed between the IGFBP-1 concentration and the intake of6polyunsaturated fatty acids (PUFA) as the proportion of energy intake (r
¼ 0.222, P ¼ 0.03), while no other correlations were detected between
levels of IGFBP-1, or phIGFBP-1 and MMP-8 with the intakes of energy,
dietary fibre or energy yielding nutrients; protein, carbohydrates, fat,
PUFA, saturated or monounsaturated fatty acids as a proportion of energy
intake (P > 0.080, for all). With respect to the dietary intakes of vitamins
and minerals, the concentration of retinol correlated inversely with the
levels of phIGFBP-1 (r¼ -0.297, P ¼ 0.004) and IGFBP-1 (r¼ -0.253, P ¼
0.014), and there were also inverse correlations between the concen-
tration of MMP-8 with those of pyridoxine (r ¼ -0.321, P ¼ 0.002) and
potassium (r ¼ -0.220, P ¼ 0.033).
4. Discussion
We revealed a weak negative relation between IGFBP-1 and systemic
low-grade inflammation as measured by the novel inflammatory marker
GlycA, but not with more traditional marker, hsCRP. In addition to the
expected relation between IGFBP-1 and glucose metabolism, we
demonstrated using modern metabolomics approach, an inverse corre-
lation between the level of phIGFBP-1 and several lipid variables,
particularly large HDL-particles, in overweight and obese women in early
pregnancy. The level of MMP- 8 displayed no association with any of the
markers of inflammation or glucose and lipid metabolism. Based on these
findings, we propose that serum IGFBP-1 reflects maternal metabolism,
particularly in relation to lipids during early pregnancy. These findings
may be important for maternal health in long-term considering the
several metabolic alterations that take place in pregnancy and are further
compromised by excess [24].
One new finding emerging from our study utilizing a modern
metabolomics approach is that there was an inverse correlation between
the level of phIGFBP-1 and several HDL-related particles, which were
independent of the serum level of insulin and prepregnancy BMI. In
previous studies in non-pregnant study groups, the level of IGFBP-1 has
been found to correlate with traditionally measured serum total HDL
cholesterol in ischaemic heart disease, type 2 diabetic patients and
healthy subjects [25, 26, 27] and in patients with unstable angina [28].
The inverse relationship between phIGFBP-1 and HDL–particles in our
study may be related to the physiological alterations in lipid metabolism
associated with pregnancy: typically an increase in the amounts of lipids,
particularly in triglycerides and total cholesterol has been reported over
the course of pregnancy [29]. Furthermore, increasing phosphorylation
of IGFBP-1 increases the affinity of IGFBP-1 to IGF-1. Thus, the altered
phosphorylation, as manifested by the lower levels of phIGFBP-1, may
result in an increased availability of IGF-1, whichmay beneficially induce
the formation of HDL-particles. Another explanation may be related to
the activity of lecithin–cholesterol acyltransferase (LCAT) and choles-
teryl ester transfer protein (CETP). LCAT is responsible for the transfer of
fatty acids to cholesterol and thus for the conversion of cholesterol into
cholesterol ester while CETP facilitates the transfer of cholesterol esters
from HDL to LDL and VLDL [30]. In this way, IGFBP-1 may participate in
the catabolism of large HDL-particles by regulating the synthesis of these
proteins. Differing from the traditional analysis for HDL assessment
applied in previous studies, we used metabolomics, which provides more
detailed information about the HDL-particles, including the particle size
and content. Larger HDL-particles have been linked to healthier meta-
bolic outcomes; thus a lower serum phIGFBP-1 concentration may be
beneficial with regard to lipid metabolism.
Our finding of the relationship of IGFBP-1 with glucose metabolism is
in accordance with previous studies in non-pregnant subjects, in whom
lower serum IGFBP-1 concentrations have been analysed in impaired
glucose tolerance [11, 31]. Furthermore, reduced IGFBP-1 levels have
been detected in women with gestational diabetes when compared to
those without this disease [16]. Regardless of the gestational diabetes
status, in all of the pregnant women studied, a low IGFBP-1 level was
related to increased insulin resistance [16], as also detected in our study.
K. Mokkala et al. Heliyon 6 (2020) e04788Low-grade inflammation is suggested to underlie metabolic distur-
bances. Previous studies have proposed that cytokines, e.g. interleukin-
1β increase the production of IGFBP-1 [32]. By using a novel inflam-
matory marker GlycA, we detected a weak, yet statistically significant
inverse association between the levels of GlycA and IGFBP-1 but not with
phIGFBP-1 or MMP-8. In a recent study of non-pregnant women with a
history of gestational diabetes, a weak correlation was observed between
MMP-8 and CRP [33], indicating that MMP-8 may be involved in
modulating inflammation. The possible explanation for the lack of a
clearer correlation in our study may be that our study population was
healthy and without the specific complications typically measured by
IGFBP-1, phIGFBP-1 and MMP-8 in late pregnancy. Nevertheless, in
general, low-grade inflammation is related to metabolism and the finding
of a relationship between IGFBP-1 levels and markers of glucose meta-
bolism and lipidomic profile suggests that IGFBP-1 is involved in
maternal metabolism during early pregnancy. We also observed an in-
verse correlation between the IGFBP-1 concentration and maternal
weight, which is in line with previous studies in pregnant women [12, 13,
14]. This suggests that IGFBP-1 may act as a mediator between maternal
weight and the alterations in glucose metabolism associated with
overweight.
In addition to metabolic and inflammatory variables, using the di-
etary data, we were able to evaluate the influence of specific nutrients
and energy intake on IGFBP-1, phIGFBP-1 and MMP-8. Fasting or
malnutrition have been shown to increase the synthesis of IGFBP-1 in a
non-pregnant population [2]. We observed a weak association between
the intake of PUFA and the IGFBP-1 level and between a few vitamins and
minerals and the concentrations of phIGFBP-1 and MMP-8. Based on our
results, the potential to modify IGFBP-1 and MMP-8 by dietary means
may be limited, although the impact of diet as a regulator of inflamma-
tory status [34] and maternal glucose metabolism has been convincingly
demonstrated [35].
Our findings may be of importance considering the metabolic health
of pregnant women. The prevalence of metabolic complications, such as
gestational diabetes during pregnancy, is increasing in association with
increasing overweight and obesity in the population. In addition, these
metabolic disturbances during pregnancy increase the risk for later
complications, such as type 2 diabetes and cardiovascular diseases. The
observed relationship between IGFBP-1 and phIGFBP-1 with maternal
metabolism suggests that the IGFBP-1 may be involved in the regulation
of maternal metabolic health and thus represent a novel target for
intervention. However, the causality and the levels resulting in clinical
manifestations need to be established, as previously either lower [11, 30]
or higher [36] serum IGFBP-1 concentrations have been measured in
association with imbalanced glucose tolerance and cardiovascular com-
plications in non-pregnant population.
The strength of this study lies in its well characterized study popu-
lation. Furthermore, we obtained comprehensive data from metab-
olomics to investigate the association between the concentrations of
IGFBP-1, phIGFBP-1 and MMP-8 with maternal metabolism. We
consider one limitation of this study is that all of the analyses were
carried during early pregnancy. Further studies will be needed to assess
the role of IGFBP-1, phIGFBP-1 and MMP-8 in maternal metabolism
throughout the entire course of pregnancy, both in normal weight
women and in relation to clinical manifestations like gestational
diabetes.
5. Conclusions
We found that the level of IGFBP-1, particularly in its phosphorylated
form, correlated with the amounts of several lipid particles especially
with lipids in large HDL particles. Furthermore, a weak inverse correla-
tion between IGFBP-1 and inflammation was observed. Our findings
suggest that the IGF-system, which has an important role in fetal devel-
opment and in regulation of glucose metabolism, may also participate in
maternal lipid metabolism during early pregnancy.7Declarations
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